These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34617444)

  • 1. Olympic anti-doping laboratory: the analytical technological road from 2016 Rio De Janeiro to 2021 Tokyo.
    Saad K; Salama S; Horvatovich P; Al Maadheed M; Georgakopoulos C
    Bioanalysis; 2021 Oct; 13(19):1511-1527. PubMed ID: 34617444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analytical progresses of the World Anti-Doping Agency Olympic laboratories: a 2016 update from London to Rio.
    Athanasiadou I; Voss S; Lyris E; Aljaber A; Alsayrafi M; Georgakopoulos C
    Bioanalysis; 2016 Nov; 8(21):2265-2279. PubMed ID: 27665839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analytical progresses of the International Olympic Committee and World Anti-Doping Agency Olympic laboratories.
    Georgakopoulos C; Saugy M; Giraud S; Robinson N; Alsayrafi M
    Bioanalysis; 2012 Jul; 4(13):1549-63. PubMed ID: 22831472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation and accreditation of anti-doping laboratories for the Olympic Games.
    Botrè F; Wu M; Boghosian T
    Bioanalysis; 2012 Jul; 4(13):1623-31. PubMed ID: 22831478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doping control from a global and national perspective.
    Fraser AD
    Ther Drug Monit; 2004 Apr; 26(2):171-4. PubMed ID: 15228160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doping control analysis at the Rio 2016 Olympic and Paralympic Games.
    Pereira HMG; Sardela VF; Padilha MC; Mirotti L; Casilli A; de Oliveira FA; de Albuquerque Cavalcanti G; Rodrigues LML; de Araujo ALD; Levy RS; Teixeira PAC; de Oliveira FAG; Duarte ACG; Carneiro ACD; Evaristo JAM; Dos Santos GRC; da Costa GCV; de Lima Castro F; Nogueira FCS; Scalco FB; Pizzatti L; de Aquino Neto FR
    Drug Test Anal; 2017 Nov; 9(11-12):1658-1672. PubMed ID: 29078043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interview: partnering with the industry: the Olympic laboratory model.
    Cowan DA; Barker CP
    Bioanalysis; 2012 Jul; 4(13):1545-8. PubMed ID: 22831471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time for change: a roadmap to guide the implementation of the World Anti-Doping Code 2015.
    Dvorak J; Baume N; Botré F; Broséus J; Budgett R; Frey WO; Geyer H; Harcourt PR; Ho D; Howman D; Isola V; Lundby C; Marclay F; Peytavin A; Pipe A; Pitsiladis YP; Reichel C; Robinson N; Rodchenkov G; Saugy M; Sayegh S; Segura J; Thevis M; Vernec A; Viret M; Vouillamoz M; Zorzoli M
    Br J Sports Med; 2014 May; 48(10):801-6. PubMed ID: 24764550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-doping policy development process in the sports world (1968~1999): focusing on IOC activities and passive response from Korea].
    Hwang ER; Kim TY
    Uisahak; 2014 Aug; 23(2):269-318. PubMed ID: 25223222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medicine and science in the fight against doping in sport.
    Catlin DH; Fitch KD; Ljungqvist A
    J Intern Med; 2008 Aug; 264(2):99-114. PubMed ID: 18702750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New and old challenges of sports drug testing.
    Botrè F
    J Mass Spectrom; 2008 Jul; 43(7):903-7. PubMed ID: 18570180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brief History of Anti-Doping.
    Ljungqvist A
    Med Sport Sci; 2017; 62():1-10. PubMed ID: 28571021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doping control analyses during the Tokyo 2020 Olympic and Paralympic Games.
    Okano M; Ikekita A; Sato M; Inoue T; Kageyama S; Akiyama K; Aoi A; Miyamoto A; Momobayashi A; Ota M; Ishige M; Sakurai H; Shiomura S; Takemine M; Watanabe Y; Hikota T
    Drug Test Anal; 2022 Nov; 14(11-12):1836-1852. PubMed ID: 36208085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ensuring high quality in anti-doping laboratories.
    Boghosian T; Barroso O; Ivanova V; Rabin O
    Bioanalysis; 2012 Jul; 4(13):1591-601. PubMed ID: 22831475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detecting - the 2004 Athens Olympic Games.
    Georgakopoulos C
    Drug Test Anal; 2020 May; 12(5):641-646. PubMed ID: 31800156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Athlete Biological Passport: an integral element of innovative strategies in antidoping.
    Vernec AR
    Br J Sports Med; 2014 May; 48(10):817-9. PubMed ID: 24659508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harmonization of anti-doping rules in a global context (World Anti-Doping Agency-laboratory accreditation perspective).
    Ivanova V; Miller JH; Rabin O; Squirrell A; Westwood S
    Bioanalysis; 2012 Jul; 4(13):1603-11. PubMed ID: 22831476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-doping analyses at the Sochi Olympic and Paralympic Games 2014.
    Sobolevsky T; Krotov G; Dikunets M; Nikitina M; Mochalova E; Rodchenkov G
    Drug Test Anal; 2014; 6(11-12):1087-101. PubMed ID: 25312500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medication use in athletes selected for doping control at the Sydney Olympics (2000).
    Corrigan B; Kazlauskas R
    Clin J Sport Med; 2003 Jan; 13(1):33-40. PubMed ID: 12544162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacy services at the PyeongChang 2018 Olympic and Paralympic Winter Games.
    Stuart M; Kwon YI; Rhie SJ
    Br J Sports Med; 2019 Sep; 53(17):1105-1110. PubMed ID: 30894336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.